Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature

Silvana Giacinti, Maria Bassanelli, Anna Maria Aschelter, Annalisa Milano, Michela Roberto, Paolo Marchetti

Research output: Contribution to journalArticlepeer-review


Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intratumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.

Original languageEnglish
Pages (from-to)6265-6269
Number of pages5
JournalAnticancer Research
Issue number11
Publication statusPublished - Nov 1 2014


  • Abiraterone
  • Castration-resistant prostate cancer
  • Prostate cancer
  • Resistance
  • Resistance to abiraterone
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature'. Together they form a unique fingerprint.

Cite this